Dyax’s mission is to discover, develop, and commercialize innovative biopharmaceuticals for unmet medical needs, while delivering outstanding value to patients, physicians and stockholders. To achieve this goal, the Company cultivates an environment that focuses on innovation—empowering those who want to a make a contribution, pursue new ideas, and expand their minds along the way. The Dyax Co-op program provides students with the opportunity to experience this culture and gain real-world industry experience.
On the average, there are 5-6 students at Dyax each Co-op term, many of whom return to Dyax for their 2nd and 3rd terms. Students in the program have the opportunity to practice critical concepts and laboratory skills and techniques learned in the classroom and to apply the scientific method to experimental protocols, yielding meaningful scientific results. In addition to their regular assignments, students are assigned a research project to be presented at the end of the term along with information about their Dyax co-op experience.
The Co-op program is a valuable partnership for NU and Dyax. The aim of the program for Dyax is to recruit talented and committed students, who are motivated by challenges, and who will make positive contributions in the near term, while building a long-term relationship with the company. For students, the Dyax experience is a critical part in learning how classroom experiences may be applied to work experiences and to shaping potential career choices.
Judy Jacques, Staff Scientist I at Dyax, is responsible for overseeing the Co-op program. She says, "Since the beginning of this program, we’ve brought in 5 of our former Co-ops to work full-time for the company upon graduation. The students we’ve worked with have been hard-working and motivated, bringing their scientific knowledge from the classroom to apply daily in our labs. They are an integral part of our scientific team and I hope to see this program progress and continue to bring in quality students."
About Dyax Corp
Dyax is focused on advancing novel biotherapeutics for unmet medical needs, with an emphasis on oncology and inflammatory indications. Dyax utilizes its proprietary drug discovery technology to identify antibody, small protein and peptide compounds for clinical development.
Dyax’s lead product candidate is DX-88, a recombinant small protein that is currently in clinical trials for its therapeutic potential in two separate indications. Dyax has successfully completed three Phase 2 trials and a Phase 3 trial of DX-88 for the treatment of hereditary angioedema (HAE). A confirmatory study, known as EDEMA4, is planned and expected to begin in the first quarter of 2007. DX-88 has orphan drug designation in the U.S. and E.U., as well as Fast Track designation in the U.S. for the treatment of acute attacks of HAE.
Independently, Dyax has successfully completed a Phase 1/2 trial of DX-88 for the prevention of blood loss during on-pump coronary artery bypass graft (CABG) procedures. Dyax is initiating a Phase 2 trial for further development of DX-88 in on-pump cardiothoracic surgery (CTS), including CABG and heart valve replacement and repair procedures.
Dyax identified DX-88 and other compounds in its pipeline using its patented phage display technology, which rapidly selects compounds that bind with high affinity and specificity to therapeutic targets. Dyax leverages this technology broadly with over 70 revenue generating licenses and collaborations for therapeutic discovery, as well as in non-core areas such as affinity separations, diagnostic imaging, and research reagents.
Dyax is headquartered in Cambridge, Massachusetts, and has antibody discovery facilities in Liege, Belgium. For online information about Dyax Corp., please visit www.dyax.com.